首页> 美国卫生研究院文献>International Journal of Chronic Obstructive Pulmonary Disease >Physicochemical compatibility of fluticasone-17-propionate nebulizer suspension with ipratropium and albuterol nebulizer solutions
【2h】

Physicochemical compatibility of fluticasone-17-propionate nebulizer suspension with ipratropium and albuterol nebulizer solutions

机译:氟替卡松17-丙酸酯雾化器悬浮液与异丙托铵和沙丁胺醇雾化器溶液的理化相容性

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

The objective of this in-vitro study was to determine whether mixtures of three nebulizable drugs are physicochemically compatible. Drug combinations were prepared by mixing the content of one respule Flutide® forte “ready to use” (fluticasone propionate) with 2 milliliter Atrovent® LS (ipratropium bromide) and 0.5 milliliter Sultanol® inhalation solution (albuterol sulfate). Test suspensions were stored at room temperature and exposed to normal laboratory light for 5 hours. Concentrations of fluticasone-17-propionate, ipratropium bromide, and albuterol sulfate were determined by using stability-indicating high-performance liquid chromatography assays with ultraviolet detection. Physical compatibility was determined by measuring pH and osmolality. Main outcome measures were the drug concentrations of the active components of the mixtures. All drug concentrations retained nearly 100% of the initial drug concentrations after mixing and storage in glass containers at room temperature. Osmolality and pH of the mixtures exhibited no significant changes and no visible changes of the mixtures were detectable over the inspection period. Mixtures of fluticasone propionate, ipratropium bromide, and albuterol sulfate inhalation drug products were shown to be physicochemically compatible over a period of 5 hrs. In order to avoid contamination and microbiological instability, mixing should only take place immediately before administration. Further investigations are needed to determine whether or not drug delivery is affected by mixing the nebulizer suspensions and to ensure that simultaneous nebulization is recommendable.
机译:这项体外研究的目的是确定三种可雾化药物的混合物是否具有物理化学相容性。通过将一种重用的即用型Flutide®forte(即氟替卡松丙酸酯)与2毫升Atrovent ® LS(异丙托溴铵)和0.5毫升Sultanol ®的含量混合来制备药物组合su>吸入溶液(硫酸丁丁醇)。将测试悬浮液在室温下保存,并在正常实验室光下暴露5小时。氟替卡松17-丙酸酯,异丙托溴铵和沙丁胺醇硫酸盐的浓度通过使用指示稳定性的高效液相色谱检测和紫外线检测来测定。物理相容性通过测量pH和重量克分子渗透压浓度来确定。主要结果指标是混合物中活性成分的药物浓度。在室温下混合并储存在玻璃容器中后,所有药物浓度均保持接近初始药物浓度的100%。在检查期间,混合物的重量克分子渗透压浓度和pH值没有显示出明显的变化,并且没有可见的变化。丙酸氟替卡松,异丙托溴铵和硫酸沙丁胺醇吸入药物产品的混合物在5小时内具有物理化学相容性。为了避免污染和微生物不稳定,应仅在给药前立即进行混合。需要进一步研究以确定混合雾化器悬浮液是否会影响药物输送,并确保建议同时雾化。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号